Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.
Purpose: to evaluate the efficacy and toxicity of a concomitant treatment using EGFR-TKI and thoracic radiation in elderly patients with esophageal Cancer. Methods:Patients(\>70 years old) with esophageal Cancer will receive thoracic radiation therapy 54-60 Gy over 30 fractions and concurrent with gefitinib 250mg/day.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
70
gefitinib 250mg/day
Thoracic radiotherapy 54-60Gy over 30 fraction
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
RECRUITINGTumor response rate
Time frame: 1 month after the thoracic radiotherapy and concurrent gefitinib treatment
The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)
Time frame: 1 month after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.